Exercise capacity and physical activity in COPD patients treated with a LAMA/LABA combination: a systematic review and meta-analysis
Abstract Background Persistent airflow limitation and dyspnoea may reduce chronic obstructive pulmonary disease (COPD) patients exercise capacity and physical activity, undermining their physical status and quality of life. Long-acting muscarinic antagonists and long-acting beta-2 agonists (LAMA/LAB...
Main Authors: | Marc Miravitlles, Juan Luís García-Rivero, Xavier Ribera, Jordi Galera, Alejandra García, Rosa Palomino, Xavier Pomares |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-022-02268-3 |
Similar Items
-
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01) -
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01) -
Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Anthony D’Urzo, et al.
Published: (2019-03-01) -
LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
by: Rogliani P, et al.
Published: (2018-10-01) -
Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)